Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 7c ; Offers Guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of $0.23, $0.07 better than the analyst estimate of $0.16. Revenue for the quarter came in at $73.47 million versus the consensus estimate of $67.7 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2025 revenue of $260-270 million, versus the consensus of $270.5 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Apollo Private Credit Fund caps redemptions at 5% - Bloomberg
• AeroVironment restates quarterly financials, citing $89M goodwill error